Biologic markers determine both the risk and the timing of recurrence in breast cancer.
Biologic markers determine both the risk and the timing of recurrence in breast cancer.
复制标题
DOI：
10.1007/s10549-011-1564-5
复制
发表时间：
2011-09
影响因子：
3.8
通讯作者：
Benz, Christopher C.
中科院分区：
文献类型：
--
作者：
Esserman, Laura J.;Moore, Dan H.;Tsing, Pamela J.;Chu, Philip W.;Yau, Christina;Ozanne, Elissa;Chung, Robert E.;Tandon, Vickram J.;Park, John W.;Baehner, Frederick L.;Kreps, Stig;Tutt, Andrew N. J.;Gillett, Cheryl E.;Benz, Christopher C.
乳腺癌有很长的自然历史。已建立的和新兴的生物标记物指出了总体风险，但不一定是复发的时间。我们对来自Guy’s医院的346例佐剂性naïve乳腺癌患者进行了至少23年的随访，并重新评估了激素受体（HR）、her2受体和分级。采用递归分划法分析疾病特异性生存（DSS）。为了验证该分析的见解，对683例淋巴结阴性、佐剂naïve乳腺癌的基因特征（增殖性和hr阴性）进行了评估，以评估其预测早期和晚期转移风险的能力，并注释了表达微阵列数据。风险划分显示，佐剂naïve淋巴结阴性结局风险主要由肿瘤受体状态和分级划分，而不是由肿瘤大小划分。HRpos阳性和her2阴性（HRpos）风险按肿瘤分级划分；低级别病例的早期风险非常低，但诊断后10年或更长时间DSS下降20%。高级别HRpos患者的发病风险超过20年。三阴性（Tneg）和her2阳性（HER2pos）病例DSS事件主要发生在前5年内。在淋巴结阳性的病例中，只有低级别的患者具有晚期风险，这表明识别增殖的增殖基因特征对于预测早期复发很重要，而不是晚期复发。使用来自四个公开可用的数据集的汇总数据，这些数据集标注了淋巴结阴性肿瘤的基因表达和结局数据，我们评估了四个预后基因特征：两个基于增殖，两个基于免疫功能。肿瘤增殖能力预测HRpos病例的早期转移风险，但不能预测晚期转移风险。免疫功能或HRneg特异性特征仅预测Tneg和HER2pos病例的早期转移风险。乳腺癌预后特征需要告知转移事件的风险和时间，并且可能最好在亚群中应用。目前的特征预测了5年内诊断的结果风险。需要HR阳性疾病的晚期风险预测因子。
Breast cancer has a long natural history. Established and emerging biologic markers address overall risk but not necessarily timing of recurrence. 346 adjuvant naïve breast cancer cases from Guy’s Hospital with 23 years minimum follow-up and archival blocks were recut and reassessed for hormone-receptors (HR), HER2-receptor and grade. Disease-specific survival (DSS) was analyzed by recursive partitioning. To validate insights from this analysis, gene-signatures (proliferative and HR-negative) were evaluated for their ability to predict early versus late metastatic risk in 683 node-negative, adjuvant naïve breast cancers annotated with expression microarray data. Risk partitioning showed that adjuvant naïve node-negative outcome risk was primarily partitioned by tumor receptor status and grade but not tumor size. HR-positive and HER2-negative (HRpos) risk was partitioned by tumor grade; low grade cases have very low early risk but a 20% fall-off in DSS 10 or more years after diagnosis. Higher grade HRpos cases have risk over >20 years. Triple-negative (Tneg) and HER2-positive (HER2pos) cases DSS events occurred primarily within the first 5 years. Among node-positive cases, only low grade conferred late risk, suggesting that proliferative gene signatures that identify proliferation would be important for predicting early but not late recurrence. Using pooled data from four publicly available data sets for node-negative tumors annotated with gene expression and outcome data, we evaluated four prognostic gene signatures: two proliferation-based and two immune function-based. Tumor proliferative capacity predicted early but not late metastatic risk for HRpos cases. The immune function or HRneg specific signatures predicted only early metastatic risk in Tneg and HER2pos cases. Breast cancer prognostic signatures need to inform both risk and timing of metastatic events and may best be applied within subsets. Current signatures predict for outcome risk within 5 years of diagnosis. Predictors of late risk for HR positive disease are needed.
登录
查看更多内容
DOI：
10.1046/j.1369-6513.2001.00119.x
发表时间：
2001-03-01
期刊：
Health expectations : an international journal of public participation in health care and health policy
影响因子：
--
作者：
Lobb, E A;Kenny, D T;Tattersall, M H
通讯作者：
Tattersall, M H
长期随访2257种可手动乳腺癌后，类固醇受体的预后价值。
影响因子：
8.8
作者：
Pichon, M F;Broet, P;Magdelenat, H;Delarue, J C;Spyratos, F;Basuyau, J P;Saez, S;Rallet, A;Courriere, P;Millon, R;Asselain, B
通讯作者：
Asselain, B
DOI：
10.1186/bcr2192
发表时间：
2008
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Reyal F;van Vliet MH;Armstrong NJ;Horlings HM;de Visser KE;Kok M;Teschendorff AE;Mook S;van 't Veer L;Caldas C;Salmon RJ;van de Vijver MJ;Wessels LF
通讯作者：
Wessels LF
影响因子：
45.3
作者：
Harvey, JM;Clark, GM;Allred, DC
通讯作者：
Allred, DC
影响因子：
4.4
作者：
Hu, Zhiyuan;Fan, Cheng;Perou, Charles M.
通讯作者：
Perou, Charles M.